182 related articles for article (PubMed ID: 29168428)
1. Standardized assessment of tumor-infiltrating lymphocytes in breast cancer: an evaluation of inter-observer agreement between pathologists.
Tramm T; Di Caterino T; Jylling AB; Lelkaitis G; Lænkholm AV; Ragó P; Tabor TP; Talman MM; Vouza E;
Acta Oncol; 2018 Jan; 57(1):90-94. PubMed ID: 29168428
[TBL] [Abstract][Full Text] [Related]
2. Interobserver Agreement Between Pathologists Assessing Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer Using Methodology Proposed by the International TILs Working Group.
Swisher SK; Wu Y; Castaneda CA; Lyons GR; Yang F; Tapia C; Wang X; Casavilca SA; Bassett R; Castillo M; Sahin A; Mittendorf EA
Ann Surg Oncol; 2016 Jul; 23(7):2242-8. PubMed ID: 26965699
[TBL] [Abstract][Full Text] [Related]
3. Inter-observer agreement of tumor infiltrating lymphocytes in primary HER2-positive breast cancer and correlation between tissue microarray and full tumor-sections.
Reznitsky FM; Jensen JD; Knoop A; Laenkholm AV
APMIS; 2022 Sep; 130(9):545-550. PubMed ID: 35639634
[TBL] [Abstract][Full Text] [Related]
4. Reproducible evaluation of tumor-infiltrating lymphocytes (TILs) using the recommendations of International TILs Working Group 2014.
Kojima YA; Wang X; Sun H; Compton F; Covinsky M; Zhang S
Ann Diagn Pathol; 2018 Aug; 35():77-79. PubMed ID: 29886396
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies.
Hida AI; Sagara Y; Yotsumoto D; Kanemitsu S; Kawano J; Baba S; Rai Y; Oshiro Y; Aogi K; Sagara Y; Ohi Y
Breast Cancer Res Treat; 2016 Jul; 158(1):1-9. PubMed ID: 27260189
[TBL] [Abstract][Full Text] [Related]
6. A new method for evaluating tumor-infiltrating lymphocytes (TILs) in colorectal cancer using hematoxylin and eosin (H-E)-stained tumor sections.
Iseki Y; Shibutani M; Maeda K; Nagahara H; Fukuoka T; Matsutani S; Kashiwagi S; Tanaka H; Hirakawa K; Ohira M
PLoS One; 2018; 13(4):e0192744. PubMed ID: 29698402
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of stromal tumour infiltrating lymphocytes and programmed cell death-ligand 1 expression in breast cancer.
Polónia A; Pinto R; Cameselle-Teijeiro JF; Schmitt FC; Paredes J
J Clin Pathol; 2017 Oct; 70(10):860-867. PubMed ID: 28373294
[TBL] [Abstract][Full Text] [Related]
8. An inter-observer Ki67 reproducibility study applying two different assessment methods: on behalf of the Danish Scientific Committee of Pathology, Danish breast cancer cooperative group (DBCG).
Laenkholm AV; Grabau D; Møller Talman ML; Balslev E; Bak Jylling AM; Tabor TP; Johansen M; Brügmann A; Lelkaitis G; Di Caterino T; Mygind H; Poulsen T; Mertz H; Søndergaard G; Bruun Rasmussen B
Acta Oncol; 2018 Jan; 57(1):83-89. PubMed ID: 29202622
[TBL] [Abstract][Full Text] [Related]
9. The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast.
Pruneri G; Lazzeroni M; Bagnardi V; Tiburzio GB; Rotmensz N; DeCensi A; Guerrieri-Gonzaga A; Vingiani A; Curigliano G; Zurrida S; Bassi F; Salgado R; Van den Eynden G; Loi S; Denkert C; Bonanni B; Viale G
Ann Oncol; 2017 Feb; 28(2):321-328. PubMed ID: 28426105
[TBL] [Abstract][Full Text] [Related]
10. Reproducibility and predictive value of scoring stromal tumour infiltrating lymphocytes in triple-negative breast cancer: a multi-institutional study.
O'Loughlin M; Andreu X; Bianchi S; Chemielik E; Cordoba A; Cserni G; Figueiredo P; Floris G; Foschini MP; Heikkilä P; Kulka J; Liepniece-Karele I; Regitnig P; Reiner A; Ryska A; Sapino A; Shalaby A; Stovgaard ES; Quinn C; Walsh EM; Zolota V; Glynn SA; Callagy G
Breast Cancer Res Treat; 2018 Aug; 171(1):1-9. PubMed ID: 29774470
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the Tumor-Stroma Ratio and Tumor-Infiltrating Lymphocytes in Colorectal Cancer: Inter-Observer Agreement Evaluation.
Kazemi A; Gharib M; Mohamadian Roshan N; Taraz Jamshidi S; Stögbauer F; Eslami S; Schüffler PJ
Diagnostics (Basel); 2023 Jul; 13(14):. PubMed ID: 37510083
[TBL] [Abstract][Full Text] [Related]
12. Tumor-Infiltrating Lymphocyte Volume Is a Better Predictor of Disease-Free Survival Than Stromal Tumor-Infiltrating Lymphocytes in Invasive Breast Carcinoma.
Vaziri Fard E; Ali Y; Wang XI; Saluja K; H Covinsky M; Wang L; Zhang S
Am J Clin Pathol; 2019 Oct; 152(5):656-665. PubMed ID: 31305879
[TBL] [Abstract][Full Text] [Related]
13. Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research.
Hendry S; Salgado R; Gevaert T; Russell PA; John T; Thapa B; Christie M; van de Vijver K; Estrada MV; Gonzalez-Ericsson PI; Sanders M; Solomon B; Solinas C; Van den Eynden GGGM; Allory Y; Preusser M; Hainfellner J; Pruneri G; Vingiani A; Demaria S; Symmans F; Nuciforo P; Comerma L; Thompson EA; Lakhani S; Kim SR; Schnitt S; Colpaert C; Sotiriou C; Scherer SJ; Ignatiadis M; Badve S; Pierce RH; Viale G; Sirtaine N; Penault-Llorca F; Sugie T; Fineberg S; Paik S; Srinivasan A; Richardson A; Wang Y; Chmielik E; Brock J; Johnson DB; Balko J; Wienert S; Bossuyt V; Michiels S; Ternes N; Burchardi N; Luen SJ; Savas P; Klauschen F; Watson PH; Nelson BH; Criscitiello C; O'Toole S; Larsimont D; de Wind R; Curigliano G; André F; Lacroix-Triki M; van de Vijver M; Rojo F; Floris G; Bedri S; Sparano J; Rimm D; Nielsen T; Kos Z; Hewitt S; Singh B; Farshid G; Loibl S; Allison KH; Tung N; Adams S; Willard-Gallo K; Horlings HM; Gandhi L; Moreira A; Hirsch F; Dieci MV; Urbanowicz M; Brcic I; Korski K; Gaire F; Koeppen H; Lo A; Giltnane J; Rebelatto MC; Steele KE; Zha J; Emancipator K; Juco JW; Denkert C; Reis-Filho J; Loi S; Fox SB
Adv Anat Pathol; 2017 Sep; 24(5):235-251. PubMed ID: 28777142
[TBL] [Abstract][Full Text] [Related]
14. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.
Salgado R; Denkert C; Demaria S; Sirtaine N; Klauschen F; Pruneri G; Wienert S; Van den Eynden G; Baehner FL; Penault-Llorca F; Perez EA; Thompson EA; Symmans WF; Richardson AL; Brock J; Criscitiello C; Bailey H; Ignatiadis M; Floris G; Sparano J; Kos Z; Nielsen T; Rimm DL; Allison KH; Reis-Filho JS; Loibl S; Sotiriou C; Viale G; Badve S; Adams S; Willard-Gallo K; Loi S;
Ann Oncol; 2015 Feb; 26(2):259-71. PubMed ID: 25214542
[TBL] [Abstract][Full Text] [Related]
15. Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.
Dieci MV; Radosevic-Robin N; Fineberg S; van den Eynden G; Ternes N; Penault-Llorca F; Pruneri G; D'Alfonso TM; Demaria S; Castaneda C; Sanchez J; Badve S; Michiels S; Bossuyt V; Rojo F; Singh B; Nielsen T; Viale G; Kim SR; Hewitt S; Wienert S; Loibl S; Rimm D; Symmans F; Denkert C; Adams S; Loi S; Salgado R;
Semin Cancer Biol; 2018 Oct; 52(Pt 2):16-25. PubMed ID: 29024776
[TBL] [Abstract][Full Text] [Related]
16. Novel tumor-infiltrating lymphocytes ultrasonography score based on ultrasonic tissue findings predicts tumor-infiltrating lymphocytes in breast cancer.
Fukui K; Masumoto N; Shiroma N; Kanou A; Sasada S; Emi A; Kadoya T; Yokozaki M; Arihiro K; Okada M
Breast Cancer; 2019 Sep; 26(5):573-580. PubMed ID: 30868399
[TBL] [Abstract][Full Text] [Related]
17. Interobserver variability in upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast: the DCISion study.
Dano H; Altinay S; Arnould L; Bletard N; Colpaert C; Dedeurwaerdere F; Dessauvagie B; Duwel V; Floris G; Fox S; Gerosa C; Jaffer S; Kurpershoek E; Lacroix-Triki M; Laka A; Lambein K; MacGrogan GM; Marchió C; Martinez DM; Nofech-Mozes S; Peeters D; Ravarino A; Reisenbichler E; Resetkova E; Sanati S; Schelfhout AM; Schelfhout V; Shaaban AM; Sinke R; Stanciu-Pop CM; Stobbe C; van Deurzen CHM; Van de Vijver K; Van Rompuy AS; Verschuere S; Vincent-Salomon A; Wen H; Bouzin C; Galant C; Van Bockstal MR
Mod Pathol; 2020 Mar; 33(3):354-366. PubMed ID: 31534203
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation of tumor-infiltrating lymphocytes in breast cancer: How to use the 2014 international guidelines?].
Joyon N; Kordahi M; Blanc-Fournier C; Lacroix-Triki M
Ann Pathol; 2017 Feb; 37(1):127-132. PubMed ID: 28159402
[TBL] [Abstract][Full Text] [Related]
19. Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00.
Pruneri G; Gray KP; Vingiani A; Viale G; Curigliano G; Criscitiello C; Láng I; Ruhstaller T; Gianni L; Goldhirsch A; Kammler R; Price KN; Cancello G; Munzone E; Gelber RD; Regan MM; Colleoni M
Breast Cancer Res Treat; 2016 Jul; 158(2):323-31. PubMed ID: 27372069
[TBL] [Abstract][Full Text] [Related]
20. Optimal threshold for stromal tumor-infiltrating lymphocytes: its predictive and prognostic value in HER2-positive breast cancer treated with trastuzumab-based neoadjuvant chemotherapy.
Liu S; Duan X; Xu L; Xin L; Cheng Y; Liu Q; Ye J; Zhang S; Zhang H; Zhu S; Li T; Liu Y
Breast Cancer Res Treat; 2015 Nov; 154(2):239-49. PubMed ID: 26498019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
